No settlement: Trial begins for Lilly's cancer drug Alimta, vitamin dosing patent
This article was originally published in Scrip
Eli Lilly executives telegraphed a few weeks ago that they had little interest in settling a patent lawsuit involving the lung cancer drug Alimta. With that foreshadowing, the trial began this week in a US court in Indiana where the big drug maker is based.
You may also be interested in...
Using Baxter’s Advate drug as a preventative therapy helped significantly reduce bleeding incidents in a yearlong study.
Mylan CEO Heather Bresch said she is looking to do a sizable deal that helps the US generic and specialty drug maker better compete in a consolidating field of rivals.
Biogen Idec CEO George Scangos is frank about his ambitions to dominate the market for hemophilia therapies, an opportunity he compares to the big biotech’s lead treating multiple sclerosis.